Zheng Mei, Lei Hongyan, Cui Yansen, Yang Daiqun, Wang Liquang, Wang Ziran
Yansen Cui, Department of Emergency, Linyi People's Hospital, Linyi 276000, China.
Hongyan Lei, Department of Emergency, Linyi People's Hospital, Linyi 276000, China.
Pak J Med Sci. 2016 Jul-Aug;32(4):811-6. doi: 10.12669/pjms.324.9518.
This study aims to observe the clinical efficacies of hyper-early low-dose alteplase thrombolysis in treating acute ischemic stroke (AIS).
Two hundred twenty AIS patients were randomly divided into group A (90 cases), group B (90 cases), and group C (40 cases). The National Institutes of Health Stroke Scale (NIHSS) scores, mRS score-evaluated prognosis, intracranial hemorrhage, and mortality of the three groups were observed before and after the treatment.
The NIHSS scores of the three groups were significantly reduced after the treatment (P<0.05), among which the NIHSS score of group A was the lowest (P<0.05); and the difference between group B and C was not significant (P>0.05). The incidence of such complications as cerebral hemorrhage in the three groups was low, and there was no significant difference among the groups (P>0.05). The modified Rankin Scale (mRS)scores of the three groups showed that group A had much better prognosis than group B and C, while the difference between group B and group C was not significant.
The hyper-early low-dose alteplase thrombolysis was safe and effective in Acute ischemic stroke (AIS).
本研究旨在观察超早期小剂量阿替普酶溶栓治疗急性缺血性脑卒中（AIS）的临床疗效。
将220例AIS患者随机分为A组（90例）、B组（90例）和C组（40例）。观察三组治疗前后的美国国立卫生研究院卒中量表（NIHSS）评分、改良Rankin量表（mRS）评分评估的预后、颅内出血情况及死亡率。
三组治疗后NIHSS评分均显著降低（P<0.05），其中A组NIHSS评分最低（P<0.05）；B组与C组差异无统计学意义（P>0.05）。三组脑出血等并发症发生率低，组间差异无统计学意义（P>0.05）。三组mRS评分显示，A组预后明显优于B组和C组，而B组与C组差异无统计学意义。
超早期小剂量阿替普酶溶栓治疗急性缺血性脑卒中（AIS）安全有效。
